Cancer therapeutics-related cardiac dysfunction(CTRCD)is receiving more attention.Risk factors assessment before cancer therapy,cardia

Abstract

Cancer therapeutics-related cardiac dysfunction(CTRCD)is receiving more attention.Risk factors assessment before cancer therapy,cardiac function monitoring during and after cancer therapy,and early detection and treatment of myocardial injury are key to preventing clinical heart failure.The incidence and severity of cardiotoxicity can be reduced by measures such as reducing drug dose,adjusting administration route,and using low toxic drugs.Cardioprotective agents including anti-heart failure drugs and dexrazoxane are important for the prevention and treatment of CTRCD.Patients with advanced heart failure may also benefit from mechanical treatments including cardiac resynchronization therapy and mechanically-assisted ventricular devices.This article reviews the recent advances in the prevention and treatment of CTRCD.

PMID: 31907138 [PubMed - in process]

9 January 2020

12:00

Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

12:00

In reply to this message

pubmed: caandvteortroorpul

A survey of outpatient Internal Medicine clinician perceptions of diagnostic error.

A survey of outpatient Internal Medicine clinician perceptions of diagnostic error.

Diagnosis (Berl). 2020 Jan 09;:

Authors: Matulis JC, Kok SN, Dankbar EC, Majka AJ